24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme can result in severe and sometimes fatal toxicity. Evidence and therapeutic recommendations are presented for DPYD genotype-directed dosing of fluoropyrimidines. This document is an update to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for DPYD genotype and fluoropyrimidine dosing (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

          Related collections

          Author and article information

          Journal
          0372741
          3058
          Clin Pharmacol Ther
          Clin. Pharmacol. Ther.
          Clinical pharmacology and therapeutics
          0009-9236
          1532-6535
          17 October 2017
          20 November 2017
          February 2018
          01 February 2019
          : 103
          : 2
          : 210-216
          Affiliations
          [1 ]University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland
          [2 ]Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
          [3 ]Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
          [4 ]Department of Biomedical Data Science, Stanford University, Stanford, California, USA
          [5 ]Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
          [6 ]Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands
          [7 ]DeBartolo Family Personalized Medicine Institute and the Department of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
          [8 ]Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
          [9 ]Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, USA
          [10 ]Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
          [11 ]Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany
          [12 ]Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany
          Author notes
          Corresponding Author: Kelly Caudle, Pharm.D., Ph.D., 262 Danny Thomas Place MS: 313, Memphis, TN 38105, Office: 901-595-3994, Cell: 901-289-7392, Fax: 901-595-3125; cpic@ 123456pharmgkb.org
          Article
          PMC5760397 PMC5760397 5760397 nihpa912821
          10.1002/cpt.911
          5760397
          29152729
          f8672eaa-2e87-4765-9edb-c0b7f538068c
          History
          Categories
          Article

          pharmacogenetics,DPYD,capecitabine,DPD,tegafur,dihydropyrimidine dehydrogenase,5-fluorouracil,CPIC,fluoropyrimidines

          Comments

          Comment on this article